Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph early_phase_1
1
25%
Ph phase_3
2
50%

Phase Distribution

1

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 3Large-scale testing
2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (33.3%)
Phase 32 (66.7%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completed

Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome

NCT06812559
completedphase_3

GnRH Antagonist Versus GnRH Agonist in Polycystic Ovary Syndrome During in Vitro Fertilization - Embryo Transfer

NCT01402336
completedearly_phase_1

Poor Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program

NCT02640976
completedphase_3

GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome

NCT01268761

Clinical Trials (4)

Showing 4 of 4 trials
NCT06812559

Progesterone Primed Ovarian Stimulation Versus GnRH Antagonist Protocols in Women With Polycystic Ovarian Syndrome

Completed
NCT01402336Phase 3

GnRH Antagonist Versus GnRH Agonist in Polycystic Ovary Syndrome During in Vitro Fertilization - Embryo Transfer

Completed
NCT02640976Early Phase 1

Poor Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program

Completed
NCT01268761Phase 3

GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4